Affymax to Present at the UBS 2012 Global Life Sciences Conference

PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq: AFFY) today announced that John Orwin, the company's chief executive officer, will present at the UBS 2012 Global Life Sciences Conference on Wednesday, September 19, 2012 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) in New York City.

A live webcast of the presentation will be available on the investors section of the Company's website at http://www.investors.affymax.com/events.cfm. A replay will also be available for 30 days following the presentation.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company based in Palo Alto, California. Affymax's mission is to discover, develop and deliver innovative therapies that improve the lives of patients with kidney disease and other serious and often life-threatening illnesses.

The company's first marketed product, OMONTYS^® (peginesatide) Injection, was approved by the U.S. Food and Drug Administration (FDA) in March 2012. For additional information, please visit www.affymax.com.